Brief: MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
19/12/2023 13:24
Dec 19 (Reuters) - Maia Biotechnology Inc MAIA.A :
* MAIA BIOTECHNOLOGY ANNOUNCES DOSE SELECTION IN THIO-101
PHASE 2
CLINICAL TRIAL FOR NON-SMALL CELL LUNG CANCER
* MAIA BIOTECHNOLOGY INC - SELECTED DOSE SHOWS UNPRECEDENTED
DISEASE CONTROL AND OVERALL RESPONSE RATES IN A NSCLC CLINICAL
TRIAL
Source text for Eikon: ID:nBw7396R2a
Further company coverage: MAIA.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale